Immunomodulatory antibody therapy of cancer: the closer, the better.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25351746.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2111 and PMC identifier 4348171.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint blockade therapies have demonstrated promising therapeutic effects; however, clinical outcomes are variable, with only a subgroup of cancer patients achieving durable complete responses. New therapeutic strategies, including local administration of immunomodulatory antibodies, have been considered as better routes for improving the overall efficacy of antibody-based therapy.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- CD40 Antigens
- Immunologic Factors
- Neoplasms
- T-Lymphocytes
- Urinary Bladder Neoplasms